During the course of our studies, we found that while both mouse and human BC lines express GD3, pretreatment with GD3 did not directly block NKT cell function (Supplemental Figure S2); rather, it indirectly modulated NKT cell activation by abrogating CD1d-mediated antigen presentation to NKT cells, as previously reported and shown in Figure 6. The gene discussed is CD1D; the disease is breast cancer.